Barbara De la Salle, President Elect of UK NEQAS and Dina Patel, Scientific Director for UK NEQAS Immunology, Immunochemistry and Allergy (IIA) offer a look inside UK NEQAS and how it works in practice. They share real-world examples to demonstrate who are UK NEQAS, and how the organisation delivers exceptional value to clinical and scientific stakeholders.
At the start of the global COVID-19 pandemic, there was a rush to ensure a rigorous antibody and antigen testing regime on a national scale. Within just four weeks, UK NEQAS had determined the relevant EQA for the antibody testing, which was accredited just eight weeks later. This was the first ISO17043 accredited antibody programme globally, a perfect showcase for how focused collaboration can deliver a critical programme quickly and efficiently.
UK NEQAS Immunology, Immunochemistry and Allergy (IIA)
is one of a network of UK NEQAS centres forming the UK NEQAS Consortium, overseen by the UK NEQAS educational charity. The COVID-19 antibody EQA success was possible thanks to teamwork across the whole UK NEQAS network.
COVID-19 antigen scheme
Log in or register FREE to read the rest
This story is Premium Content and is only available to registered users. Please log in at the top of the page to view the full text.
If you don't already have an account, please register with us completely free of charge.